ArticleVascular health and risk management2026
Impact of Comorbidity Clusters on Quality of Life in Chronic Heart Failure.
Article in Vascular health and risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Grouping comorbidities can better reflect the intrinsic relationships among complications. We aimed to explore the relationships between comorbidity groups and dynamic changes in health-related quality of life (HRQoL) in patients with chronic heart failure (CHF). Patients and Methods: A total of 1533 patients with CHF were included. Demographic and clinical variables were recorded during hospitalization. HRQoL was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline and at 3 and 12 months. Latent class analysis was used to identify comorbidity groups among patients with CHF. This method identifies latent subgroups by analyzing patterns in their comorbidities. Repeated-measures analysis of variance (ANOVA) was used to assess the relationships between comorbidity groups and dynamic changes in KCCQ scores. Results: Three comorbidity clusters were identified: the young/valvular heart disease (VHD) group, the elderly/coronary heart disease (CHD) group, and the high-comorbidity burden group. The young group had a relatively lower comorbidity burden and the best HRQoL, followed by the elderly/CHD group, while the high-comorbidity burden group showed the worst HRQoL. The overall summary scores, clinical summary scores, social limitations, physical limitations, and self-efficacy were significantly highest in the high-comorbidity burden group. In addition, at 3 months the symptom scores had decreased in all three groups. Repeated-measures ANOVA showed that the comorbidity groups were significantly associated with dynamic changes in HRQoL through time and group effects. Conclusion: There were significant differences in the baseline characteristics and dynamic changes of HRQoL among different comorbidity clusters. Patients in the high-comorbidity burden group performed the worst in terms of quality of life, but the improvement was the most significant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.